Immatics Announces Full Year 2024 Financial Results and Business Update
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients;…
Newsrooms
Application areas and exposure principles for in vitro lung cell research
Explore Application Areas and Exposure Principles for in vitro Inhalation Research VITROCELL® devices are designed to e…
Analog Devices at Embedded World 2025: Intelligent Solutions for a Secure, Connected Future
Analog Devices (ADI) will be connecting with industry leaders in Nuremberg for Embedded World 2025. Visitors to the ADI…
Common cough syrup ingredient shows promise in treating serious lung disease
Lung fibrosis occurs when lung tissue becomes damaged, thickened, and scarred, leading to breathing difficulties tha…
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Arice…
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phas…
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidia…
Collaborative Breakthrough in Lung-on-Chip Technology
Collaborative Breakthrough in Lung-on-Chip Technology: AlveoliX, Vitrocell, University of Bern and Helmholtz Institute f…
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-pres…
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients…